SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study.
SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study.
复制标题
DOI：
10.1016/j.lanepe.2022.100502
复制
发表时间：
2022-11
影响因子：
20.9
通讯作者：
Middleton, Rodden M.
中科院分区：
文献类型：
--
作者：
Frahm, Niklas;Fneish, Firas;Ellenberger, David;Haas, Judith;Loebermann, Micha;Parciak, Tina;Peters, Melanie;Poehlau, Dieter;Rodgers, Jeff;Roeper, Anna-Lena;Schilling, Sarah;Stahmann, Alexander;Temmes, Herbert;Zettl, Uwe K.;Middleton, Rodden M.
疫苗为多发性硬化症（PwMS）患者提供了有效的保护，以防止严重的COVID-19疾病过程。然而，关于SARS-CoV-2疫苗在PwMS中耐受性的代表性真实世界数据有限。我们旨在分析德国和英国（UK）PwMS中SARS-CoV-2疫苗接种后的疫苗接种反应（VR）和MS恶化，特别是关于性别特异性差异。德国多发性硬化协会和英国MS登记处分别在第一次（X1）和第二次SARS-CoV-2疫苗接种（X2）后通过在线系统获得健康数据：社会人口统计学和临床数据、使用的疫苗、VR、MS恶化（恶化或新发MS症状，仅德国）和复发（仅德国）。按性别分层分析VR和MS恶化的频率。在X1（X2）之后，2346（1835）名德国PwMS和3796（683）名英国PwMS参与了研究。最常见的疫苗接种方案是德国的两剂托西那美仑（77.1%，1424/1847）和英国的两剂AZD 1222（61.3%，419/683）。最常见的VR是疲劳、头痛和疼痛（注射部位），女性比男性更常见。德国PwMS在X2后报告的VR频率高于X1（65.4%[1201/1835] vs. 61.2%[1435/2346]），而英国患者则相反（X1 vs. X2：48.7%[1849/3796] vs. 30.0%[205/683]）。19.0%（445/2346）的德国PwMS发生MS恶化，没有导致性别特异性差异。疲劳和步态障碍是最常见的MS恶化症状。女性PwMS报告经历VR比男性更频繁。需要纵向数据，使有效的声明，长期MS恶化和持久的VR。德国多发性硬化症协会（DMSG Bundesverband e. V.），Biogen，布里斯托Myers Squibb，Merck Serono，Mylan，诺华，罗氏和赛诺菲。
Vaccines offer people with multiple sclerosis (PwMS) an effective protection against severe COVID-19 disease courses. However, representative real-world data on the tolerability of SARS-CoV-2 vaccines in PwMS are limited. We aimed at analysing vaccination reactions (VRs) and MS deterioration following SARS-CoV-2 vaccinations in German and United Kingdom (UK) PwMS, especially regarding gender-specific differences. The German Multiple Sclerosis Society and the UK MS Registry acquired health data via an online system following the first (X1) and second SARS-CoV-2 vaccination (X2), respectively: sociodemographic and clinical data, vaccines used, VRs, MS deterioration (worsened or new MS symptoms, Germany only) and relapses (Germany only). The frequencies of VRs and MS deterioration were analysed stratified by gender. Following X1 (X2), 2346 (1835) German PwMS and 3796 (683) UK PwMS participated in the study. The most frequent vaccination scheme was two-dose tozinameran for Germany (77·1%, 1424/1847) and two-dose AZD1222 for the UK (61·3%, 419/683). The most common VRs were fatigue, headache and pain (at the injection site) and occurred more often in women compared with men. German PwMS reported VRs more frequently after X2 vs. X1 (65·4% [1201/1835] vs. 61·2% [1435/2346]), while for UK patients it was the opposite (X1 vs. X2: 48·7% [1849/3796] vs. 30·0% [205/683]). MS deterioration occurred in 19·0% (445/2346) of the German PwMS without resulting in gender-specific differences. Fatigue and gait impairment were the most frequent deteriorated MS symptoms. Female PwMS reported experiencing VRs more often than men. Longitudinal data are needed to enable valid statements regarding long-term MS deterioration and long-lasting VRs. German Multiple Sclerosis Society (DMSG Bundesverband e.V.), Biogen, Bristol Myers Squibb, Merck Serono, Mylan, Novartis, Roche and Sanofi.
登录
查看更多内容
DOI：
10.1016/s2665-9913(21)00181-8
发表时间：
2021-08
期刊：
The Lancet. Rheumatology
影响因子：
--
作者：
Boekel L;Kummer LY;van Dam KPJ;Hooijberg F;van Kempen Z;Vogelzang EH;Wieske L;Eftimov F;van Vollenhoven R;Kuijpers TW;van Ham SM;Tas SW;Killestein J;Boers M;Nurmohamed MT;Rispens T;Wolbink G
通讯作者：
Wolbink G
DOI：
10.1212/nxi.0000000000001118
发表时间：
2022-01
期刊：
Neurology(R) neuroimmunology & neuroinflammation
影响因子：
--
作者：
Garjani A;Middleton RM;Nicholas R;Evangelou N
通讯作者：
Evangelou N
影响因子：
5.8
作者：
Salter, A.;Stahmann, A.;Marrie, R. A.
通讯作者：
Marrie, R. A.
DOI：
10.1177/13524585211003476
发表时间：
2021-05
期刊：
Multiple sclerosis (Houndmills, Basingstoke, England)
影响因子：
--
作者：
Achiron A;Dolev M;Menascu S;Zohar DN;Dreyer-Alster S;Miron S;Shirbint E;Magalashvili D;Flechter S;Givon U;Guber D;Stern Y;Polliack M;Falb R;Gurevich M
通讯作者：
Gurevich M
影响因子：
4
作者：
Ehde DM;Roberts MK;Humbert AT;Herring TE;Alschuler KN
通讯作者：
Alschuler KN